BRAF and cancer: Activating somatic mutations of BRAF, most commonly via substitution of valine for glutamic acid at codon 600 (BRAF V600E), have been shown to result in constitutive activation of the MAPK pathway in several human cancers, including malignant melanomas and thyroid tumors [45].